New Discovery: Obesity is a delay again! Large retrospective analysis showed that chemotherapy was poor in obese breast cancer patients.

Author: Bamboo introduction: how much harm does obesity bring? In the case of breast cancer, before diagnosis, for Asian people, the higher BMI, the higher the risk of breast cancer; after diagnosis, for every 5 kg weight gain, all-cause mortality increased by 12%, and specific mortality increased by 13%.during the treatment, obesity is also a troublemaker, so we can't see the patients well.existing studies have shown that breast cancer patients with obesity or overweight will greatly reduce the effect of chemotherapy.based on a retrospective analysis of data from large clinical trials, an international team of researchers concluded that overweight or obese breast cancer patients are much less effective than ordinary patients receiving docetaxel, one of the most widely used chemotherapy drugs in the world.their study was published in the Journal of clinical oncology.in most European countries, more than 50% of women are overweight or obese (according to WHO definition, body mass index (BMI) is higher than 25 kg / m2).this is the case for more than 63% of women in the United States, and it is expected to increase further in the next few years.it is not known to all that obese women have a higher risk of breast cancer and that obese women have a higher risk of recurrence.in addition, although many cancer patients are overweight or obese, it is generally not clear to determine the efficacy of anticancer drugs based on their BMI.analysis of 2800 patients in this study, data from clinical trials of more than 2800 patients with breast cancer were analyzed by research teams from the University of Leuven, the Jules boldai Institute in Brussels, Belgium, the University of Milan and the National Cancer Institute of Italy.this study lasted more than ten years, and researchers collected a lot of patient data.in the trial, patients were treated with or without docetaxel.then, the researchers observed how many patients relapsed and how many died.their statistical analysis of the data showed that overweight and obese patients treated with docetaxel had poorer outcomes than those with lean (BMI between 18.5 and 25 kg / m2).this difference was not observed in patients receiving chemotherapy regimens that did not include docetaxel.raising public awareness has drawn attention to the treatment of overweight and obese cancer patients with docetaxel.if subsequent studies confirm that the finding is only related to the pharmacological properties of docetaxel, it may also be applicable to patients with other types of cancer treated with docetaxel, such as prostate cancer or lung cancer. these results also make researchers wonder whether other chemotherapeutic drugs in the same family, such as paclitaxel, will show the same effect. more research needs to be done before changing the treatment plan. patients who have questions about docetaxel can discuss it with their doctor. professor biganzoli of the Department of medical statistics and the Research Center for data science of the University of Milan and the National Cancer Institute of Italy said that the public needed to better understand the link between BMI and breast cancer. however, in the medical and research community, researchers need to pay more attention to how obesity affects biology, progress and breast cancer treatment efficacy. reference: Recommended Reading: fight against the epidemic situation, translational medicine network content team report: [breakthrough] scientists from the three countries jointly developed a new "detoxification version" of erythromycin, and the side effects were greatly reduced! [PNAs] Yale University Research! The switch to control the inflammation caused by overeating has been found! [new findings] black raspberries, or a new "Star" in reducing skin inflammation, can damage arteries and increase the risk of heart disease, according to Ohio State University research